Cancel

Together, we are more than scleroderma

Scleroderma (also known as systemic sclerosis) is a rare disease that can affect connective tissue throughout the whole body, both inside and out.[1,2] Everyone with scleroderma has a slightly different combination of symptoms, which is why there are many different experiences of scleroderma.[2]

Because scleroderma is so rare, you might not know much about it. It can be hard to find clear information on scleroderma and difficult to know what it all means.

More than Scleroderma™ has been developed to support and guide you during your journey, by providing information and resources that you can trust, all in one place.

It summarises the current scientific knowledge, latest news, and real-life experiences, and provides handy resources to help you along the way.

Scleroderma explained
Across the European Union and the United States, a rare disease is defined as affecting fewer than 1 person in every 2,000. [3,4]
adjusting to scleroderma diagnosis
Adjusting to your diagnosis
You can’t compare scleroderma to any other disease. There’s no standard course, everybody’s different.
Scleroderma and you

Patient stories

Listen to stories from others with scleroderma

I’m retired and I really loved my work. But now I love other things.
You have to keep going.
Don’t panic, and find pleasure in the small things.
I just have to think positive, that’s how I think of it.
More stories
scleroderma patient grazia
Lung problems
I realised I had a problem with my lungs when I couldn’t do the things I did before, like hiking in the mountains. But I take my time and enjoy doing what’s possible for me.
Understanding lung problems
Support groups
You are not alone in the world of scleroderma. Information, support and advice are available. Find your local support group below.
Europe
Spain
Find your support group

References

  1. Derrett-Smith E, Denton C. Systemic sclerosis: clinical features and management. Medicine. 2010;38(2):109-15.

  2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-567.

  3. European Commission. Rare Diseases. https://ec.europa.eu/health/rare_diseases/policy_en Accessed July 2017.

  4. U.S. Food & Drug Administration. Orphan Drugs Act – Relevant Excerpts. Updated Aug 2013. https://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoapplyfor
    orphanproductdesignation/ucm364750.htm     Accessed May 2017.

Back to top

This document and its contents are property of Boehringer Ingelheim (third party sources are indicated) and are, inter alia, protected by copyright law. Complete or partial passing on to third parties as well as copying, reproduction, publication or any other use by third parties is not permitted.

© 2010-2019 Boehringer Ingelheim GmbH
All rights reserved